查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574936

直接作用抗病毒藥物市場，按類型、按適應症、按給藥途徑、按分佈、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Direct-acting Antiviral Drug Market, By Type, By Indication, By Route of Administration, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年直接作用抗病毒藥物市場規模為2,840,932萬美元，2024年至2032年複合年成長率為5.50%。

直接作用抗病毒藥物市場-市場動態

提高對肝炎和愛滋病毒的認知和篩檢計畫。

由於幾個關鍵促進因素，包括肝炎和愛滋病毒感染率的上升，直接作用抗病毒（DAA）藥物的市場正在擴大。隨著人們對這些疾病的認知不斷增強，越來越多的人接受篩檢，從而提高診斷率。改善醫療保健服務和這些疾病的教育也是促成因素。此外，藥物開發的最新進展帶來了更有效、更快速的治療方法，使其備受追捧。

美國疾病管制與預防中心 (CDC) 報告稱，2021 年，約 25% 的乙型肝炎和丙型肝炎患者被診斷出來，這凸顯了對有效治療的迫切需求。這種意識的提高和篩檢計劃的改進對於有效管理和治療病毒感染至關重要。因此，對 DAA 的需求持續成長，塑造了抗病毒治療的未來。

直接作用抗病毒藥物市場-關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 5.50% 左右的複合年成長率成長

根據類型細分，預計 NS5A 蛋白將在 2023 年顯示最大的市場佔有率

根據適應症細分，2023年C型肝炎病毒為主導類型

根據給藥途徑細分，2023年口服是領先類型

從分銷細分來看，醫院藥局是2023年的主導類型

按地區分類，北美是 2023 年的主要收入來源

直接作用抗病毒藥物市場-細分分析：

全球直接作用抗病毒藥物市場根據類型、適應症、給藥途徑、分佈和地區進行細分。

市場依類型分為三類：NS3/4A 蛋白酶、NS5A 蛋白和 NS5B RNA 依賴性 RNA 聚合酶。 NS5A 蛋白質部分是直接作用抗病毒藥物市場中最突出的部分。這是因為 NS5A 抑制劑在治療丙型肝炎方面非常有效，並且被用於許多成功的治療方案中。它們有助於阻止病毒複製和組裝的能力，從而為患者帶來更好的結果。對包括 NS5A 抑制劑在內的聯合療法的需求不斷成長，使得這一細分市場佔據主導地位。因此，NS5A 蛋白藥物對於推進丙型肝炎治療方案和改善患者健康至關重要。

根據適應症，市場分為四類：C型肝炎病毒、愛滋病毒感染/愛滋病、流感和預防。丙型肝炎病毒部分是直接作用抗病毒藥物市場中最突出的部分。這是因為C型肝炎影響著全世界數百萬人，對有效治療產生了強烈需求。專為丙型肝炎設計的直接作用抗病毒藥物已顯示出很高的治癒率並被廣泛使用。隨著人們對該疾病認知的提高，越來越多的患者尋求這些治療，從而使這一細分市場佔據主導地位。總體而言，丙型肝炎藥物在改善健康結果和減少疾病傳播方面發揮著至關重要的作用。

直接作用抗病毒藥物市場-地理洞察

直接作用抗病毒（DAA）藥物市場在北美最大，尤其是美國，對C型肝炎和愛滋病毒的有效治療有很高的需求。歐洲緊追在後，德國、法國和英國等國家投資抗病毒療法。亞太地區是一個快速成長的地區，其推動力是醫療保健意識和可近性不斷提高，特別是在中國和印度等國家。拉丁美洲也顯示出潛力，旨在對抗病毒感染的醫療保健措施不斷增加。中東和非洲市場佔有率較小，但由於醫療基礎設施改善，正在逐漸擴大。總體而言，北美地區處於領先地位，但其他地區在 DAA 市場上也取得了重大進展。

直接作用抗病毒藥物市場-競爭格局：

直接作用抗病毒 (DAA) 藥物市場由吉利德科學 (Gilead Sciences) 和艾伯維 (AbbVie) 等主要參與者引領，這些公司以其對丙型肝炎和愛滋病毒的有效治療而聞名。其他公司，包括默克和百時美施貴寶，也提供各種抗病毒選擇，專注於創新和研究以保持競爭力。許多公司建立合作夥伴關係以增強其產品線並進入更廣泛的市場。隨著專利到期，Mylan 和 Hetero Labs 等學名藥製造商紛紛介入，提供成本更低的替代品。該市場正在全球範圍內擴張，重點是讓治療變得負擔得起且易於獲得。公司面臨監管挑戰，需要進行廣泛的臨床試驗才能獲得批准。總體而言，市場格局是動態的，其特徵是激烈的競爭和對改善病患照護的承諾。

最新進展：

2024年9月，Cocrystal Pharma成功將其口服泛病毒蛋白酶抑制劑CDI-988推進至1期多劑量遞增試驗，該試驗將評估該藥物在健康志願者中的安全性、耐受性和最佳劑量。

目錄

第1章：直接作用抗病毒藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按類型分類的直接作用抗病毒藥物市場片段
    • 按適應症分類的直接作用抗病毒藥物市場片段
    • 按給藥途徑分類的直接作用抗病毒藥物市場片段
    • 按分佈分類的直接作用抗病毒藥物市場片段
    • 按國家分類的直接作用抗病毒藥物市場片段
    • 按地區分類的直接作用抗病毒藥物市場片段
  • 競爭洞察

第 3 章：直接作用抗病毒藥物主要市場趨勢

  • 直接作用抗病毒藥物市場促進因素
    • 市場促進因素的影響分析
  • 直接作用抗病毒藥物市場限制
    • 市場限制影響分析
  • 直接作用抗病毒藥物市場機會
  • 直接作用抗病毒藥物市場未來趨勢

第 4 章：直接作用抗病毒藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：直接作用抗病毒藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：直接作用抗病毒藥物市場格局

  • 2023年直接作用抗病毒藥物市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：直接作用抗病毒藥物市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • NS3/4A蛋白酶
    • NS5A蛋白
    • NS5B RNA依賴性RNA聚合酶

第 8 章：直接作用抗病毒藥物市場 - 依適應症分類

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 丙型肝炎病毒
    • HIV 感染/愛滋病
    • 流感
    • 預防

第 9 章：直接作用抗病毒藥物市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 靜脈
    • 口服
    • 皮下
    • 專題

第 10 章：直接作用抗病毒藥物市場 - 按分佈

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 醫院藥房
    • 網路藥局
    • 零售藥房

第 11 章：直接作用抗病毒藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美直接作用抗病毒藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模和預測（按指標）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按分佈）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲直接作用抗病毒藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按指標）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模與預測（按分佈）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區直接作用抗病毒藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模與預測（依指標）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模與預測（按分佈）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲直接作用抗病毒藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（按指標）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模與預測（按分佈）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲直接作用抗病毒藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模及預測（依指標）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按分佈）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第12章：主要供應商分析-直接作用抗病毒藥物產業

  • 競爭儀表板
  • 公司簡介
    • Gilead Sciences
    • AbbVie
    • Merck & Co.
    • Bristol-Myers Squibb
    • Johnson & Johnson
    • GlaxoSmithKline
    • AstraZeneca
    • Roche
    • Novartis
    • ViiV Healthcare
    • Eisai
    • Hetero Labs
    • Mylan
    • Fujifilm Toyama Chemical
    • Sofinnova Partners

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3935

REPORT HIGHLIGHT

Direct-acting Antiviral Drug Market size was valued at USD 28,409.32 Million in 2023, expanding at a CAGR of 5.50% from 2024 to 2032.

The direct-acting antiviral (DAA) drug market focuses on medications that directly target and block the virus that causes hepatitis and HIV. These drugs work by interfering with the virus's ability to multiply, helping to clear the infection from the body. The drugs are important because they often have fewer side effects and work faster than older treatments. This makes them a preferred option for many patients. As awareness of these diseases grows, more people are seeking DAA drugs, leading to an increase in market demand. Overall, these drugs play a crucial role in improving health outcomes for those affected by viral infections.

Direct-acting Antiviral Drug Market- Market Dynamics

Growing awareness and screening programs for hepatitis and HIV.

The market for direct-acting antiviral (DAA) drugs is expanding due to several key drivers, including the increasing prevalence of hepatitis and HIV infections. As awareness of these diseases grows, more people are getting screened, leading to higher diagnosis rates. Improved healthcare access and education about these conditions are also contributing factors. Moreover, recent advancements in drug development have resulted in more effective treatments that act quickly, making them highly sought after.

The Centers for Disease Control and Prevention (CDC) reported that, in 2021, about 25% of people living with hepatitis B and C were diagnosed, highlighting the urgent need for effective therapies. This rising awareness and improved screening programs are crucial for managing and treating viral infections effectively. As a result, the demand for DAAs continues to grow, shaping the future of antiviral treatments.

Direct-acting Antiviral Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.50% over the forecast period (2024-2032)

Based on Type segmentation, The NS5A Protein was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Hepatitis C virus was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Distribution segmentation, Hospital Pharmacy was the leading type in 2023

based on region, North America was the leading revenue generator in 2023

Direct-acting Antiviral Drug Market- Segmentation Analysis:

The Global Direct-acting Antiviral Drug Market is segmented based on Type, Indication, Route of Administration, Distribution, and Region.

The market is divided into three categories based on Type: NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA Polymerase. The NS5A Protein segment is the most prominent in the direct-acting antiviral drugs market. This is because NS5A inhibitors are highly effective in treating hepatitis C and are used in many successful treatment regimens. They help block the virus's ability to replicate and assemble, leading to better outcomes for patients. The growing demand for combination therapies that include NS5A inhibitors makes this segment dominant. As a result, NS5A Protein drugs are crucial for advancing hepatitis C treatment options and improving patient health.

The market is divided into four categories based on Indications: Hepatitis C Virus, HIV Infection/AIDS, Influenza, and Prophylaxis. The Hepatitis C virus segment is the most prominent in the direct-acting antiviral drug market. This is because hepatitis C affects millions of people worldwide, creating a strong demand for effective treatments. Direct-acting antivirals specifically designed for hepatitis C have shown high cure rates and are widely used. As awareness about the disease increases, more patients are seeking these treatments, making this segment dominant. Overall, hepatitis C drugs play a crucial role in improving health outcomes and reducing the disease's spread.

Direct-acting Antiviral Drug Market- Geographical Insights

The direct-acting antiviral (DAA) drug market is largest in North America, particularly the United States, where there is high demand for effective treatments for hepatitis C and HIV. Europe follows closely, with countries like Germany, France, and the UK investing in antiviral therapies. Asia-Pacific is a rapidly growing region, driven by increasing awareness and access to healthcare, especially in countries like China and India. Latin America also shows potential, with rising healthcare initiatives aimed at combating viral infections. The Middle East and Africa have a smaller market share but are gradually expanding due to improved healthcare infrastructure. Overall, North America leads, but other regions are making significant progress in the DAA market.

Direct-acting Antiviral Drug Market- Competitive Landscape:

The direct-acting antiviral (DAA) drug market is led by major players like Gilead Sciences and AbbVie, known for their effective treatments for hepatitis C and HIV. Other companies, including Merck and Bristol-Myers Squibb, also offer a variety of antiviral options, focusing on innovation and research to stay competitive. Many firms form partnerships to enhance their product lines and reach broader markets. As patents expire, generic manufacturers like Mylan and Hetero Labs enter the scene, providing lower-cost alternatives. The market is expanding globally, with a strong emphasis on making treatments affordable and accessible. Companies face regulatory challenges, needing extensive clinical trials for approval. Overall, the landscape is dynamic, marked by fierce competition and a commitment to improving patient care.

Recent Developments:

In September 2024, Cocrystal Pharma successfully advanced its oral pan-viral protease inhibitor, CDI-988, into Phase 1 multiple-ascending dose trials, which will evaluate the drug's safety, tolerability, and optimal dosing in healthy volunteers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences
  • AbbVie
  • Merck & Co.
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • GlaxoSmithKline
  • AstraZeneca
  • Roche
  • Novartis
  • ViiV Healthcare
  • Eisai
  • Hetero Labs
  • Mylan
  • Fujifilm Toyama Chemical
  • Sofinnova Partners

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • NS3/4A Protease
  • NS5A Protein
  • NS5B RNA-Dependent RNA polymerase

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Hepatitis C Virus
  • HIV Infection/ AIDS
  • Influenza
  • Prophylaxis

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Subcutaneous
  • Topical

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacy
  • Online Drug Store
  • Retail Pharmacy

GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Direct-acting Antiviral Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Direct-acting Antiviral Drug Market Snippet by Type
    • 2.1.2. Direct-acting Antiviral Drug Market Snippet by Indication
    • 2.1.3. Direct-acting Antiviral Drug Market Snippet by Route of Administration
    • 2.1.4. Direct-acting Antiviral Drug Market Snippet by Distribution
    • 2.1.5. Direct-acting Antiviral Drug Market Snippet by Country
    • 2.1.6. Direct-acting Antiviral Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Direct-acting Antiviral Drug Key Market Trends

  • 3.1. Direct-acting Antiviral Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Direct-acting Antiviral Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Direct-acting Antiviral Drug Market Opportunities
  • 3.4. Direct-acting Antiviral Drug Market Future Trends

4. Direct-acting Antiviral Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Direct-acting Antiviral Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Direct-acting Antiviral Drug Market Landscape

  • 6.1. Direct-acting Antiviral Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Direct-acting Antiviral Drug Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. NS3/4A Protease
    • 7.1.3. NS5A Protein
    • 7.1.4. NS5B RNA-Dependent RNA polymerase

8. Direct-acting Antiviral Drug Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Hepatitis C Virus
    • 8.1.3. HIV Infection/ AIDS
    • 8.1.4. Influenza
    • 8.1.5. Prophylaxis

9. Direct-acting Antiviral Drug Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Intravenous
    • 9.1.3. Oral
    • 9.1.4. Subcutaneous
    • 9.1.5. Topical

10. Direct-acting Antiviral Drug Market - By Distribution

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacy
    • 10.1.3. Online Drug Store
    • 10.1.4. Retail Pharmacy

11. Direct-acting Antiviral Drug Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Direct-acting Antiviral Drug Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Direct-acting Antiviral Drug Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Direct-acting Antiviral Drug Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Direct-acting Antiviral Drug Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Direct-acting Antiviral Drug Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Direct-acting Antiviral Drug Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences
    • 12.2.2. AbbVie
    • 12.2.3. Merck & Co.
    • 12.2.4. Bristol-Myers Squibb
    • 12.2.5. Johnson & Johnson
    • 12.2.6. GlaxoSmithKline
    • 12.2.7. AstraZeneca
    • 12.2.8. Roche
    • 12.2.9. Novartis
    • 12.2.10. ViiV Healthcare
    • 12.2.11. Eisai
    • 12.2.12. Hetero Labs
    • 12.2.13. Mylan
    • 12.2.14. Fujifilm Toyama Chemical
    • 12.2.15. Sofinnova Partners

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us